ResMed Inc.
ResMed Announces Strong Q1 FY2025 Results and Dividend Declaration
Summary
ResMed Inc. reported a robust first quarter for fiscal year 2025, with year-over-year revenue growth of 11%, an operating profit increase of 34%, and a quarterly cash dividend of $0.53 per share declared. The company's net income grew by 42% to $311 million, and non-GAAP diluted earnings per share increased to $2.20. The dividend, with a record date of November 7, 2024, and payable on December 12, 2024, reflects ResMed's strong financial performance and commitment to returning value to shareholders.
Profitelligence Alerts
Get alerts for RMD
Be first to know when ResMed Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About ResMed Inc.
ResMed Inc. is an innovative leader in the development and manufacturing of devices focused on improving the quality of sleep and respiratory health. Operating globally, ResMed specializes in producing advanced equipment for sleep apnea therapy, chronic obstructive pulmonary disease (COPD), and various respiratory conditions. The company's offerings include a range of cutting-edge products like continuous positive airway pressure (CPAP) devices, bilevel systems, and ventilators, designed to enhance patient comfort and compliance. ResMed is also at the forefront of integrating cloud-connected devices to support improved patient monitoring and telemedicine services. The healthcare industry, particularly the medical device sector, benefits significantly from ResMed's contributions, as the company aims to address the growing needs associated with sleep and respiratory conditions. By focusing on both personal and overarching health care solutions, ResMed plays a crucial role in enhancing patient quality of life, thereby solidifying its position as a key player in the global health and respiratory care markets.
Official SEC Documents
Advertisement